BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 10030093)

  • 1. [Immunohistochemical tumor markers in infiltrating ductal breast carcinoma].
    Gallegos M; González S; León A; Claure R; Goñi I; Andrade L; Duarte I
    Rev Med Chil; 1998 Oct; 126(10):1216-23. PubMed ID: 10030093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ductal carcinoma in situ of the breast: correlation between histologic classifications and biologic markers.
    Moreno A; Lloveras B; Figueras A; Escobedo A; Ramon JM; Sierra A; Fabra A
    Mod Pathol; 1997 Nov; 10(11):1088-92. PubMed ID: 9388058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p53 in breast cancer. Its relation to histological grade, lymph-node status, hormone receptors, cell-proliferation fraction (ki-67) and c-erbB-2. Immunohistochemical study of 153 cases.
    Sirvent JJ; Salvadó MT; Santafé M; Martínez S; Brunet J; Alvaro T; Palacios J
    Histol Histopathol; 1995 Jul; 10(3):531-9. PubMed ID: 7579801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apocrine ductal carcinoma in situ of the breast: histologic classification and expression of biologic markers.
    Leal C; Henrique R; Monteiro P; Lopes C; Bento MJ; De Sousa CP; Lopes P; Olson S; Silva MD; Page DL
    Hum Pathol; 2001 May; 32(5):487-93. PubMed ID: 11381366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. COX-2 expression in DCIS: correlation with VEGF, HER-2/neu, prognostic molecular markers and clinicopathological features.
    Perrone G; Santini D; Vincenzi B; Zagami M; La Cesa A; Bianchi A; Altomare V; Primavera A; Battista C; Vetrani A; Tonini G; Rabitti C
    Histopathology; 2005 May; 46(5):561-8. PubMed ID: 15842638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utility of a simplified molecular classification of tumors for predicting survival of patients with invasive ductal breast carcinoma.
    Muñoz-Díaz MM; Fernández-Aceñero MJ; Salvadores P; Schneider J
    Anticancer Res; 2009 Nov; 29(11):4727-30. PubMed ID: 20032426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation between genetic and biological aspects in primary non-metastatic breast cancers and corresponding synchronous axillary lymph node metastasis.
    D'Andrea MR; Limiti MR; Bari M; Zambenedetti P; Montagutti A; Ricci F; Pappagallo GL; Sartori D; Vinante O; Mingazzini PL
    Breast Cancer Res Treat; 2007 Mar; 101(3):279-84. PubMed ID: 16835704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activated Akt signaling pathway in invasive ductal carcinoma of the breast: correlation with HER2 overexpression.
    Park SS; Kim SW
    Oncol Rep; 2007 Jul; 18(1):139-43. PubMed ID: 17549359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. c-erbB-2, p53 protein expression and steroid hormone receptors in breast carcinomas: an immunohistochemical study.
    Yokota T; Imamura M; Teshima S; Suzuki H; Tezuka F; Kikuchi S; Kunii Y; Yamauchi H
    Anticancer Res; 1999; 19(5B):4007-12. PubMed ID: 10628345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemical detection of p53 protein expression in breast cancer in young Kuwaiti women.
    Temmim L; Baker H; Sinowatz F
    Anticancer Res; 2001; 21(1B):743-8. PubMed ID: 11299837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic and predictive factors of invasive ductal breast carcinomas.
    Lialiaris TS; Georgiou G; Sivridis E; Kareli D; Tripsiannis G; Papageorgiou A; Chrisafi S; Kritsi Z; Giatromanolaki A
    J BUON; 2010; 15(1):79-88. PubMed ID: 20414932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemical co-expression of c-erbb-2/Neu oncoprotein, altered tumour suppressor (p53) protein, EGF-R and EMA in histological subtypes of infiltrating duct carcinoma of the breast.
    Sharma BK; Ray A; Kaur S; Gupta S
    Indian J Exp Biol; 1999 Mar; 37(3):223-7. PubMed ID: 10641149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TRAIL death receptor-4 expression positively correlates with the tumor grade in breast cancer patients with invasive ductal carcinoma.
    Sanlioglu AD; Korcum AF; Pestereli E; Erdogan G; Karaveli S; Savas B; Griffith TS; Sanlioglu S
    Int J Radiat Oncol Biol Phys; 2007 Nov; 69(3):716-23. PubMed ID: 17512128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mammographically-detected ductal in situ carcinoma of the breast analyzed with a new classification. A study of 127 cases: correlation with estrogen and progesterone receptors, p53 and c-erbB-2 proteins, and proliferative activity.
    Zafrani B; Leroyer A; Fourquet A; Laurent M; Trophilme D; Validire P; Sastre-Garau X
    Semin Diagn Pathol; 1994 Aug; 11(3):208-14. PubMed ID: 7831532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. C-erbB-2 expression is a better predictor for survival than galectin-3 or p53 in early-stage breast cancer.
    Logullo AF; Lopes AB; Nonogaki S; Soares FA; Netto MM; Nishimoto IN; Brentani MM
    Oncol Rep; 2007 Jul; 18(1):121-6. PubMed ID: 17549356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intraductal spread of invasive breast carcinoma has a positive correlation with c-erb B-2 overexpression and vascular invasion.
    Jing X; Kakudo K; Murakami M; Nakamura Y; Nakamura M; Yokoi T; Yang Q; Oura S; Sakurai T
    Cancer; 1999 Aug; 86(3):439-48. PubMed ID: 10430252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation of HER-2/neu protein overexpression with other prognostic and predictive factors in invasive ductal breast cancer.
    Ivkovic-Kapicl T; Knezevic-Usaj S; Djilas-Ivanovic D; Panjkovic M
    In Vivo; 2007; 21(4):673-8. PubMed ID: 17708365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Relationship of oncogene C-erbB2 expression to ER, PR and PS2 in breast cancer and its prognostic significance].
    Yang JQ; Chen L; Xing TY
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 May; 35(3):334-6, 357. PubMed ID: 15181828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concurrent overexpression of p53 and c-erbB-2 correlates with accelerated cycling and concomitant poor prognosis in node-negative breast cancer.
    Rudolph P; Alm P; Olsson H; Heidebrecht HJ; Fernö M; Baldetorp B; Parwaresch R
    Hum Pathol; 2001 Mar; 32(3):311-9. PubMed ID: 11274641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation of clinical, pathological status, hormone receptor and C-erbB-2 oncoprotein in breast cancer patients.
    Aryandono T; Harijadi ; Ghozali A
    Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():600-6. PubMed ID: 10895217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.